The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated 5-year local control (LC), metastasis-free survival (MFS), and overall survival (OS) data from a phase I study of nilotinib plus radiation (RT) in high-risk chordoma.
 
Gregory Michael Cote
Consulting or Advisory Role - Agios; Epizyme; PharmaMar
Research Funding - Agios (Inst); Bavarian Nordic; Bayer (Inst); Boston Biomedical (Inst); CBA Research (Inst); Eisai (Inst); Epizyme (Inst); Macrogenics (Inst); Merck KGaA (Inst); PharmaMar (Inst); Plexxikon (Inst); Springworks Therapeutics (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Thomas F. DeLaney
Honoraria - Oakstone Publishing; UpToDate; Wolters Kluwer
 
Ruoyu Miao
No Relationships to Disclose
 
Joseph H. Schwab
No Relationships to Disclose
 
Kevin Raskin
No Relationships to Disclose
 
Santiago Lozano Calderón
No Relationships to Disclose
 
John Thomas Mullen
No Relationships to Disclose
 
Alex Bernard Haynes
No Relationships to Disclose
 
Francis J. Hornicek
Stock and Other Ownership Interests - Biome AI; Bone Solutions
Consulting or Advisory Role - American Association of Tissue Banks; FDA; Globus; International Society of Limb Salvage
Research Funding - Stryker
 
Yen-Lin Chen
No Relationships to Disclose
 
Edwin Choy
Consulting or Advisory Role - Immune Design
Research Funding - Amgen (Inst); AstraZeneca (Inst); Exelixis (Inst); Immune Design (Inst); Iterion Therapeutics (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Novartis (Inst)